Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7204239 + tirzepatide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
RO7204239 + tirzepatide is a **combination therapy being investigated for the treatment of obesity and overweight with at least one weight-related comorbidity** in adults without diabetes mellitus. RO7204239 (also known as RG6237) is an experimental agent developed by Roche, studied for efficacy, safety, and pharmacological properties alongside tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. The combination is being evaluated in a phase 2, randomized, double-blind, placebo-controlled clinical trial for its effect on body weight loss over 48 weeks, with additional observation for weight maintenance and metabolic outcomes[1][2][3][4][5].
- Other names
- RO7204239 + tirzepatide
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on RO7204239 + tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7204239 + tirzepatide.